ICER Releases Report on Therapies for Anemia in Chronic Kidney Disease

The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for roxadustat (AstraZeneca) for treatment of anemia in chronic kidney disease (CKD).  This preliminary draft marks the midpoint of ICER’s eight-month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.

The Draft Evidence Report and Draft Voting Questions are now open to public comment until 5 PM ET on January 5, 2021. All stakeholders are invited to submit formal comments by email to publiccomments@icer-review.org.